New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2012
18:38 EDTDCTH, DHIL, ASNA, ELX, MW, GRMN, FNSR, ALGN, VRA, AMBAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Finisar (FNSR), up 6%... Ascena Retail (ASNA), up 2%... Ambarella (AMBA), up 1.5%... ALSO HIGHER: Garmin (GRMN), up 4% after being added to S&P 500, effective December 11 close... Diamond Hill Investment Group (DHIL), up 5% after announcing $8 per share special dividend... DOWN AFTER EARNINGS: Vera Bradley (VRA), down 9%... Men's Warehouse (MW), down 8% after earnings and lowered guidance... ALSO LOWER: Delcath Systems (DCTH), down 11% after announcing a modified NDA with the FDA... Align Technology (ALGN), down 4% after saying it sees EPS, revenue at lower end of previous guidance... Emulex (ELX), down 3% after announcing acquisition, reaffirming previous guidance.
News For FNSR;ASNA;AMBA;GRMN;DHIL;VRA;MW;DCTH;ALGN;ELX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
10:42 EDTGRMNOptions with increasing implied volatility: VNET GRMN
November 20, 2014
13:15 EDTGRMNRaymond James says an outright sale of Garmin is unlikely
Subscribe for More Information
10:37 EDTGRMNOptions with increasing implied volatility
Subscribe for More Information
07:27 EDTGRMNGarmin volatility elevated
Garmin November call option implied volatility is at 40, December is at 35; compared to its 26-week average of 29 according to Track Data, suggesting large near term price movement.
November 19, 2014
13:16 EDTGRMNGarmin is an unlikely acquisition target, says Citigroup at Citigroup
Subscribe for More Information
11:32 EDTGRMNGarmin calls active on takeover speculation
Garmin November 57.5 and December 60 calls are active on total call volume of 8,100 contracts (500 puts) on takeover speculation. November call option implied volatility is at 36, December is at 34; compared to its 26-week average of 29 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
10:23 EDTGRMNRumor: Garmin strength attributed to takeover speculation
Shares of Garmin (GRMN) are moving higher on speculation Honeywell (HON) has approached the company.
November 18, 2014
11:28 EDTAMBAGoPro rises after company, shareholders file to sell 10.36M shares
Shares of GoPro (GRPO) are rising in early trade after the company filed to sell 10.36M shares of its stock on behalf of the company and its stockholders. WHAT'S NEW: GoPro announced in a prospectus that it is selling about 1.29M shares of class A common stock and that selling stockholders are selling 9.073M shares of class A common stock. The holders of the company's outstanding class B common stock will hold approximately 96.1% of the voting power following this offering, with its executive officers and directors and their affiliates holding approximately 65% and CEO Nicholas Woodman holding approximately 42.5% after his sale of about 4.08M shares of class A common stock in this offering, the company explained. GoPro estimated that it will receive net proceeds of $97.1M from the sale of class A shares, assuming a public offering price of $79.15 per share. The company said it expects to use the net proceeds of this offering for general corporate purposes including working capital, adding that it may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies or assets. "However, we have no present commitments or agreements to enter into any acquisitions or make any investments," GoPro noted. WHAT'S NOTABLE: On November 10, GoPro shares slipped after its CEO acknowledged he planned to sell some of his stake as part of this stock offering. In a regulatory filing at that time, the company shared an email message sent by Woodman to employees, in which he assured that he plans to be a "significant shareholder in GoPro for a long time." Additionally, on its earnings conference call this morning, Dick's Sporting Goods (DKS) management said it continues to be "extremely enthusiastic" about the electronics category, particularly wearables, GoPro cameras, and the Fitbit activity tracker. ANALYST OPINION: In a note to investors this morning, Pacific Crest said channel checks for high end GoPros are looking better than expected. The firm said it sees upside to the upcoming quarter for Ambarella (AMBA), which provides components used by GoPro in its cameras. Pacific Crest increased its price target on Ambarella shares to $55 from $47 and maintains its Outperform rating on the stock. PRICE ACTION: In morning trading, shares of GoPro rose 4.2% to $84.92, while Ambarella (AMBA) gained 5.8% to $51.60.
November 17, 2014
10:02 EDTASNAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:30 EDTASNAAscena Retail downgraded to Market Perform from Outperform at Avondale
November 10, 2014
13:35 EDTFNSRCapital Research Global reports 11.9% passive stake in Finisar
Subscribe for More Information
06:40 EDTDCTHDelcath Systems treats first patient in Melphalan/HDS Phase 2 trial
Delcath Systems announced that the first treatment has been performed in the company's Global Phase 2 Clinical Program for first-line treatment of patients with unresectable hepatocellular carcinoma, or HCC, or primary liver cancer. A team led by Prof. Dr. med. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at Goethe University Hospital Frankfurt, Germany, treated its first case on November 5. The treating physicians reported that the patient was treated successfully. In Europe, the Company's Phase 2 trial program will investigate the safety and efficacy of Melphalan/HDS treatment without sorafenib in patients with unresectable liver cancer confined to the liver, evaluate tumor response as measured by modified Response Evaluation Criteria in Solid Tumor, or mRECIST, and assess progression-free survival and safety. Additional analyses will be conducted to characterize the systemic exposure of melphalan administered by Melphalan/HDS, as well as assess patient-reported clinical outcomes, or quality-of-life. The Company's Phase 2 trial program is expected to include four to seven centers in Europe and the United States, and will seek to enroll approximately 30 patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use